Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study of HW201877 Capsules for Participants With Moderate to Severe Active Inflammatory Bowel Disease (IBD)

A Phase IIa, Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of HW201877 Capsule in the Treatment of Moderate to Severe Active Inflammatory Bowel Disease (IBD)

This is a Phase IIa, open-label, multicenter clinical trial that plans to enroll approximately 20 patients each with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) who have had an inadequate response, loss of response, or intolerance to prior therapies. Participants will receive 12 weeks of the investigational study drug to provide a preliminary assessment of its efficacy and safety.

Panoramica dello studio

Stato

Non ancora reclutamento

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

40

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Hubei
      • Wuhan, Hubei, Cina, 430060
        • Renmin hospital of Wuhan University
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Aged 18 to 75 years (inclusive).
  • Body Mass Index (BMI) ≥18 kg/m^2 at screening.
  • Participants must have been diagnosed with ulcerative colitis or Crohn's disease at least 3 months prior to the start of screening, and confirmed by endoscopy and histology at screening.
  • Meeting one of the criteria for moderate to severe active disease.
  • Participants have had an inadequate response, loss of response, or intolerance to at least one conventional therapy and/or advanced therapy, or are unable to receive these treatments for other reasons.
  • Female participants of childbearing potential must have a negative pregnancy test and must not be breastfeeding; male and female participants must not plan to become pregnant or father a child throughout the clinical study period and for 3 months after the last dose, and must agree to use medically accepted reliable contraceptive methods during the study period and for 3 months after the last dose.
  • Fully understand the study, voluntarily sign the informed consent form, and be able to comply with the study procedures and follow-up examination requirements.

Exclusion Criteria:

  • Presence of any of the following cohort-specific conditions (as applicable to the enrolled cohort):

Cohort 1 (UC patients): Ulcerative colitis with rectal involvement only (disease extent limited to within 10 cm from the anal verge); Cohort 2 (CD patients): Presence of fistulas (excluding perianal fistulas), perianal abscess (except those without active symptoms after incision and drainage), extensive small bowel resection (>100 cm), or short bowel syndrome, where efficacy cannot be assessed by CDAI/SES-CD.

  • Evidence of or clinical suspicion of other active gastrointestinal inflammatory diseases including: indeterminate colitis (IBDU), intestinal Behçet's disease, colitis ischaemic, radiation colitis, drug-induced enteropathy, enteritis infectious, diverticulitis-associated colitis, etc.

  • Presence of symptomatic intestinal strictures (including those with pre-stenotic dilation and obstructive symptoms), abdominal abscess, fulminant colitis and toxic megacolon, intestinal perforation.

  • Participants who have previously undergone intestinal surgery or who may require surgical treatment during the study (including but not limited to: colostomy/ileostomy, total proctocolectomy, partial colectomy).

  • Long-term exclusive enteral nutrition or parenteral nutrition prior to screening.

  • Endoscopic findings at screening revealing gastrointestinal dysplasia (atypical hyperplasia)/cancer, except for completely resected low-grade dysplasia.

  • Active Clostridium difficile infection or other active intestinal infection within 30 days prior to baseline assessment; or positive Clostridium difficile toxin assay or other enteric pathogen screening within 30 days prior to baseline assessment with infection-related clinical symptoms, except for simple intestinal colonization (without evidence of infection).

  • Participants who currently have or have a history of any of the following infections:

    1. Clinically significant infection within 1 month prior to screening;
    2. Any infection requiring antimicrobial therapy within 2 weeks prior to screening;
    3. Any other history of infection that the investigator believes may be exacerbated by participation in this study.
  • Based on interferon-gamma release assay (e.g., QuantiFERON®-TB Gold test, T-SPOT®.TB, etc.) results, clinical symptoms, and/or chest imaging findings, the participant is judged to possibly have active Mycobacterium tuberculosis (TB) infection.

  • At screening, positive hepatitis B test results, positive Hepatitis C Virus Antibody (HCV Ab), positive Human Immunodeficiency Virus Antibody (HIV Ab), positive Treponema pallidum Antibody (TP Ab).

  • Any congenital or acquired immunodeficiency (e.g., HIV infection, organ transplantation, etc.)

  • Use of any drug or therapeutic measure prohibited by the protocol.

  • Malignancy within 5 years prior to screening (except locally excised non-melanoma skin cancer and radically treated cervical carcinoma in situ); existing non-melanoma skin cancer must be excised prior to enrollment.

  • Any significant laboratory finding will result in exclusion from the study.

  • Clinically significant electrocardiogram abnormalities, such as QTc interval prolongation (male > 450 ms, female > 470 ms) (QTcF = QT/(RR^0.33)), long QT syndrome, etc.

  • History of moderate to severe cardiac failure congestive (New York Heart Association [NYHA] functional class ≥ III), cerebrovascular or cardiovascular events, or severe bleeding events within 3 months prior to screening, which in the investigator's judgment makes the participant unsuitable for participation in the clinical study.

  • Severe, progressive, or uncontrolled cardiovascular, cerebrovascular, hepatic, renal, pulmonary, gastrointestinal, ophthalmic, hematopoietic, endocrine, neurological, psychiatric, or other abnormalities that, in the investigator's assessment, make the participant unsuitable for enrollment in this study.

  • Pregnant or breastfeeding (pregnancy is defined as the state from conception until termination of pregnancy).

  • Allergy to the investigational product or any ingredient in the investigational product.

  • History of alcohol abuse (consumption of 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine) or drug abuse within one year prior to screening.

  • Total blood donation exceeding 500 mL within 8 weeks prior to the first dose, or planned blood donation during the study period.

  • Conditions that, in the investigator's judgment, may affect the safety and efficacy evaluation of the investigational product.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: HW201877

HW201877 oral capsule,12W

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Cohort 1 • Proportion of participants achieving clinical remission based on the modified Mayo score at Week 12;
Lasso di tempo: At week 12
At week 12
Cohort 2 Co-primary endpoints: • Proportion of participants achieving symptomatic remission at Week 12;
Lasso di tempo: At week 12
At week 12
Cohort 2 Co-primary endpoints: • Proportion of participants achieving endoscopic response at Week 12.
Lasso di tempo: At week 12
At week 12

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
Cohort 1 • Proportion of participants achieving endoscopic response at Week 12;
Lasso di tempo: at week 12
at week 12
Cohort 1 • Proportion of participants achieving histologic remission at Week 12;
Lasso di tempo: at week 12
at week 12
Cohort 2 • Proportion of participants achieving symptomatic response at each visit;
Lasso di tempo: at week 12
at week 12
Cohort 2 • Change from baseline in CDAI score at each visit;
Lasso di tempo: at week 12
at week 12
Cohort 2 • Change from baseline in total score of Inflammatory Bowel Disease Questionnaire (IBDQ) at each visit.
Lasso di tempo: at week 12
at week 12
Safety Endpoints • Incidence of AEs and SAEs during the study;
Lasso di tempo: at week 12
at week 12
Safety Endpoints • Incidence of discontinuation of study treatment due to AEs and SAEs during the study;
Lasso di tempo: at week 12
at week 12
Safety Endpoints • Incidence of AEs and SAEs leading to withdrawal from the study during the study;
Lasso di tempo: at week 12
at week 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 dicembre 2027

Date di iscrizione allo studio

Primo inviato

5 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • HW201877-201

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi